What kind of medicine is ivonib tablets? Treatment mechanism and clinical application analysis

Ivosidenib is an oral small molecule inhibitor targeting isocitrate dehydrogenase 1 (IDH1) mutations. It is mainly used to treat specific types of cancers carrying IDH1 mutations. IDH1 gene mutations can lead to abnormal cell metabolism and promote tumor cell proliferation and survival. Ivonib can selectively inhibit the activity of IDH1 mutant enzyme, thereby restoring normal cell metabolism and inhibiting tumor growth.

The therapeutic mechanism of ivonib is mainly by inhibiting the IDH1 mutant protein and reducing the carcinogenic metabolite 2-hydroxyglutarate (2-HG) catalyzed by it. 2-HG can cause epigenetic abnormalities, affect cell differentiation, and cause hematopoietic stem cells or other tissue cells to stagnate in an immature state, ultimately leading to the occurrence of leukemia or solid tumors. Ivonib inhibits cancer progression by reducing 2-HG levels and restoring normal cell differentiation.

In terms of clinical application, ivosidenib has been approved for the treatment of relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), as well as some patients with IDH1-mutated cholangiocarcinoma. Studies have shown that ivonib has a higher response rate in AML patients, and some patients can obtain long-term remission. In the field of cholangiocarcinoma, ivonib is used to treat patients with advanced or metastatic cholangiocarcinoma who have received at least one systemic therapy in the past. It can delay disease progression and improve patient survival.
Since ivonib is mainly targeted at patients with IDH1 mutations, genetic testing is required before use to confirm whether the patient is suitable for the drug. In addition, ivonib may cause side effects such as QT interval prolongation and differentiation syndrome, which requires close monitoring and management under the guidance of a doctor. Overall, as a precision treatment drug, ivonib provides a new treatment option for patients with IDH1 mutation-related cancers and improves patients’ survival hope.
Reference link: https://www.tibsovo.com/